🔗 Share this article World Health Organization Sounds Warning Over Critical Lack of Obesity Injections Less than one in 10 people eligible to benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it issues its first advice on the drugs. Given more than one billion individuals worldwide now classified as obese, it is urging increased and just access to GLP-1 medication. Based on forecasts, over two billion could be obese by 2030 unless action is taken. "Our new guidance acknowledges that obesity is a chronic disease that can be treated with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are major obstacles to widespread availability to the jabs that can assist patients in reducing considerable body mass, explains the organization. Skinny Jab Supply Crisis Even under the present most optimistic scenario, the manufacturing of such drugs could only cover around 100 million people – under 10% of the global need, according to the health organization. The guideline calls on countries and companies to expand access, through measures including licensing agreements. A patent on a key compound – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026. The Way Weight-Loss Drugs Work The injections imitate a body's own hormone to slow digestion, curb appetite and increase feelings of fullness so people eat less. People typically begin shedding pounds in the initial weeks of commencing the weekly injections. Studies suggests users may put most of the weight back on after a year of discontinuing the drug, because their typical appetite return. To be above a healthy weight elevates your likelihood for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and certain malignancies. Obesity concerns individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.
Less than one in 10 people eligible to benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it issues its first advice on the drugs. Given more than one billion individuals worldwide now classified as obese, it is urging increased and just access to GLP-1 medication. Based on forecasts, over two billion could be obese by 2030 unless action is taken. "Our new guidance acknowledges that obesity is a chronic disease that can be treated with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are major obstacles to widespread availability to the jabs that can assist patients in reducing considerable body mass, explains the organization. Skinny Jab Supply Crisis Even under the present most optimistic scenario, the manufacturing of such drugs could only cover around 100 million people – under 10% of the global need, according to the health organization. The guideline calls on countries and companies to expand access, through measures including licensing agreements. A patent on a key compound – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026. The Way Weight-Loss Drugs Work The injections imitate a body's own hormone to slow digestion, curb appetite and increase feelings of fullness so people eat less. People typically begin shedding pounds in the initial weeks of commencing the weekly injections. Studies suggests users may put most of the weight back on after a year of discontinuing the drug, because their typical appetite return. To be above a healthy weight elevates your likelihood for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and certain malignancies. Obesity concerns individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.